Home » Posts tagged with » Roche
Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquires DNA sequencing technology company Stratos Genomics

Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The transaction is expected to help Roche advance the development of its nanopore sequencer through the access to Sequencing by Expansion (SBX), Stratos Genomics’ unique chemistry. Roche said that once developed, […]

Roche launches v-TAC blood gas digital solution

Swiss healthcare company Roche has launched a new blood gas digital solution called Roche v-TAC, which is said to be designed to enhance patient care. The new digital diagnostic solution is said to help clinicians to get better results for arterial blood gas values from patients having respiratory or metabolic abnormalities by using a less […]

Continue reading …
Roche cobas HPV test for cervical screening gets FDA nod for use on cobas 6800/8800 Systems

Swiss healthcare company Roche has bagged approval from the US Food and Drug Administration to use its cobas HPV test on the fully automated cobas 6800/8800 Systems for detecting cervical cancer in women. The cobas HPV test has been designed to detect the presence of high-risk human papillomavirus (HPV) DNA in cervical samples from women […]

Continue reading …
Actemra coronavirus clinical trial : Genentech gets FDA nod for COVID-19 trial

Actemra coronavirus clinical trial : Genentech has been given approval by the US Food & Drug Administration (FDA) to undertake the phase 3 COVACTA trial to assess the safety and efficacy of intravenous Actemra (tocilizumab) along with standard of care in hospitalized adults having severe COVID-19 pneumonia. The Roche subsidiary will carry out the randomized, […]

Continue reading …
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Continue reading …
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798

Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Roche’s cancer drug Rituxan (rituximab). Rituxan, which is a CD20-directed cytolytic antibody, has approval across various regions for the […]

Continue reading …
Roche to acquire US biotech company Promedior for $1.4bn

Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]

Continue reading …
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

Continue reading …
FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

Continue reading …
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Continue reading …
Page 1 of 212